{"classes":[{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% CI were not estimable due to insufficient number of participants and/or events.","groupId":"OG000","lowerLimit":"16.62","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants administered with daratumumab 16 mg/kg on Day 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 milligram (mg) on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG000","title":"Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT population analysis set included all enrolled participants who signed the informed consent during Phase 2.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Phase 2: Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}